Neurogene (NGNE) vs OmniAb (OABI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
OmniAb (OABI) has outperformed Neurogene (NGNE) over the past year, gaining 163.2% versus a loss of 16.3%. Over five years, OABI leads with a -52.0% price change compared with -81.7% for NGNE. OmniAb is the larger company by market cap ($696.4 million vs $528.3 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NGNE | OABI |
|---|---|---|
| Share price | $26.40 | $4.79 |
| Market cap | $528.30M | $696.42M |
| 1-day change | -0.38% | +2.79% |
| YTD return | +28.16% | +158.92% |
| 1-year return | -16.35% | +163.19% |
| 5-year return | -81.72% | -51.96% |
| EPS (TTM) | $-5.04 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $43.66 | $5.43 |
| 52-week low | $15.93 | $1.30 |
| Distance from 52-week high | -39.53% | -11.79% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +195.00% | +73.90% |
| Average volume | 249.87K | 1.47M |
| Shares outstanding | 20.01M | 145.39M |
| Employees | 131 | 89 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OABI has outperformed NGNE by 179.5 percentage points over the past year.
About Neurogene
NGNE stock →Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees
About OmniAb
OABI stock →OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 89 employees
NGNE vs OABI FAQ
Which is bigger, Neurogene or OmniAb?
OmniAb (OABI) is larger, with a market capitalization of $696.42M compared with $528.30M for Neurogene (NGNE).
Which stock has performed better over the past year, NGNE or OABI?
OABI returned +163.19% over the past 12 months, compared with -16.35% for NGNE (price return, excluding dividends). Past performance does not predict future results.
Are Neurogene and OmniAb in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Neurogene and Biotechnology: Commercial Physical & Biological Resarch for OmniAb.